Skip to main content

Advertisement

SpringerLink
Log in

IMP3 Predicts Invasion and Prognosis in Human Lung Adenocarcinoma

  • Published:
Lung Aims and scope Submit manuscript

Abstract

Purpose

Insulin-like growth factor II mRNA-binding protein 3 (IMP3) is an oncofetal protein associated with several aggressive and advanced cancers. Whether IMP3 can predict invasion, and prognosis in patients with human lung adenocarcinoma (LAC) remains unclear.

Methods

Ninety-five LAC and 75 non-tumor lung tissue samples were included in a tissue microarray. IMP3 expression was assessed by immunohistochemical examination. Correlation between IMP3 expression levels, clinicopathological characteristics, and overall prognosis was evaluated. In a separate in vitro study, RNA interference method was applied for knockdown of IMP3 gene in human LAC cell lines. Invasive potential of LAC cells was then evaluated by transwell migration assay.

Results

IMP3 immunoreactivity was observed in 39 out of 95 (41.1 %) LAC patients, but not in non-tumor lung tissues. IMP3 expression levels were closely associated with histological grade (P = 0.037), TNM stage (P = 0.034), and lymph node metastasis (P = 0.011). Patients presenting with positive IMP3 expression (P = 0.000), an advanced TNM stage (P = 0.000), and lymph node metastasis (P = 0.001) had a worse overall survival, compared to those lacking these characteristics. Both IMP3 expression (hazard ratio [HR], 2.310; 95 % confidence interval [CI] 1.192–4.476; P = 0.013) and TNM stage (HR 2.338; 95 % CI 1.393–3.925; P = 0.001) were independent predictors of poor prognosis. The invasive potential of LAC cells was significantly inhibited by IMP3 knockdown.

Conclusion

IMP3 appears to play an important role in tumor invasion in patients with LAC and may serve as a useful prognostic biomarker in these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90

    Article  PubMed  Google Scholar 

  2. Lortet-Tieulent J, Soerjomataram I, Ferlay J et al (2014) International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women. Lung Cancer 84:13–22

    Article  CAS  PubMed  Google Scholar 

  3. Nakamura H, Saji H (2014) Worldwide trend of increasing primary adenocarcinoma of the lung. Surg Today 44:1004–1012

    Article  PubMed  Google Scholar 

  4. Okada M (2013) Subtyping lung adenocarcinoma according to the novel 2011 IASLC/ATS/ERS classification: correlation with patient prognosis. Thorac Surg Clin 23:179–186

    Article  PubMed  Google Scholar 

  5. Gu W, Fang S, Gao L et al (2013) Clinic significance of microRNA-99a expression in human lung adenocarcinoma. J Surg Oncol 108:248–255

    Article  CAS  PubMed  Google Scholar 

  6. Chen W, Zheng R, Zhang S et al (2013) The incidences and mortalities of major cancers in China, 2009. Chin J Cancer 32:106–112

    Article  PubMed Central  PubMed  Google Scholar 

  7. Chilosi M, Murer B (2010) Mixed adenocarcinomas of the lung: place in new proposals in classification, mandatory for target therapy. Arch Pathol Lab Med 134:55–65

    PubMed  Google Scholar 

  8. Nielsen J, Christiansen J, Lykke-Andersen J et al (1999) A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 19:1262–1270

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Liao B, Hu Y, Brewer G (2011) RNA-binding protein insulin-like growth factor mRNA-binding protein 3 (IMP-3) promotes cell survival via insulin-like growth factor II signaling after ionizing radiation. J Biol Chem 286:31145–31152

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Findeis-Hosey JJ, Xu H (2011) The use of insulin like-growth factor II messenger RNA binding protein-3 in diagnostic pathology. Hum Pathol 42:303–314

    Article  CAS  PubMed  Google Scholar 

  11. Sitnikova L, Mendese G, Liu Q et al (2008) IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res 14:1701–1706

    Article  CAS  PubMed  Google Scholar 

  12. Jiang Z, Lohse CM, Chu PG et al (2008) Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. Cancer 112:2676–2682

    Article  PubMed Central  PubMed  Google Scholar 

  13. Hoffmann NE, Sheinin Y, Lohse CM et al (2008) External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer 112:1471–1479

    Article  PubMed Central  PubMed  Google Scholar 

  14. Zheng W, Yi X, Fadare O et al (2008) The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol 32:304–315

    Article  PubMed  Google Scholar 

  15. Wei Q, Yan J, Fu B et al (2014) IMP3 expression is associated with poor survival in cervical squamous cell carcinoma. Hum Pathol 45:2218–2224

    Article  CAS  PubMed  Google Scholar 

  16. Vikesaa J, Hansen TV, Jonson L et al (2006) RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J 25:1456–1468

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Bell JL, Wachter K, Muhleck B et al (2013) Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression? Cell Mol Life Sci 70:2657–2675

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Hwang YS, Xianglan Z, Park KK et al (2012) Functional invadopodia formation through stabilization of the PDPN transcript by IMP-3 and cancer-stromal crosstalk for PDPN expression. Carcinogenesis 33:2135–2146

    Article  CAS  PubMed  Google Scholar 

  19. Findeis-Hosey JJ, Yang Q, Spaulding BO et al (2010) IMP3 expression is correlated with histologic grade of lung adenocarcinoma. Hum Pathol 41:477–484

    Article  CAS  PubMed  Google Scholar 

  20. Yuan RH, Wang CC, Chou CC et al (2009) Diffuse expression of RNA-binding protein IMP3 predicts high-stage lymph node metastasis and poor prognosis in colorectal adenocarcinoma. Ann Surg Oncol 16:1711–1719

    Article  PubMed  Google Scholar 

  21. Li D, Yan D, Tang H et al (2009) IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. Ann Surg Oncol 16:3499–3506

    Article  PubMed  Google Scholar 

  22. Gong Y, Woda BA, Jiang Z (2014) Oncofetal protein IMP3, a new cancer biomarker. Adv Anat Pathol 21:191–200

    Article  CAS  PubMed  Google Scholar 

  23. Bellezza G, Cavaliere A, Sidoni A (2009) IMP3 expression in non-small cell lung cancer. Hum Pathol 40:1205–1206

    Article  PubMed  Google Scholar 

  24. Beljan PR, Durdov MG, Capkun V et al (2012) IMP3 can predict aggressive behaviour of lung adenocarcinoma. Diagn Pathol 7:165

    Article  Google Scholar 

  25. Dhwc S (2002) International union against cancer (UICC): TNM classification of malignant tumors. Wiley, New York

    Google Scholar 

  26. Travis WD, Brambilla E, Müller-Hermelink HK et al. (2004) Pathology and genetics of tumours of the lung, pleura, thymus and heart, vol 10. Lyon: IARC Press. World Health Organization Classification of Tumors

  27. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25(4):402–408

    Article  CAS  PubMed  Google Scholar 

  28. Mueller-Pillasch F, Lacher U, Wallrapp C et al (1997) Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 14:2729–2733

    Article  CAS  PubMed  Google Scholar 

  29. Jiang Z, Chu PG, Woda BA et al (2006) Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol 7:556–564

    Article  CAS  PubMed  Google Scholar 

  30. Zheng W, Yi X, Fadare O et al (2008) The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol 32:304–315

    Article  PubMed  Google Scholar 

  31. Yuan RH, Wang CC, Chou CC et al (2009) Diffuse expression of RNA-binding protein IMP3 predicts high-stage lymph node metastasis and poor prognosis in colorectal adenocarcinoma. Ann Surg Oncol 16:1711–1719

    Article  PubMed  Google Scholar 

  32. Liao B, Hu Y, Herrick DJ et al (2005) The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem 280:18517–18524

    Article  CAS  PubMed  Google Scholar 

  33. Jeng YM, Chang CC, Hu FC et al (2008) RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma. Hepatology 48:1118–1127

    Article  CAS  PubMed  Google Scholar 

  34. Findeis-Hosey JJ, Xu H (2012) Insulin-like growth factor II-messenger RNA-binding protein-3 and lung cancer. Biotech Histochem 87:24–29

    Article  CAS  PubMed  Google Scholar 

  35. Pasiliao CC, Chang CW, Sutherland BW et al (2015) The involvement of insulin-like growth factor 2 binding protein 3 (IMP3) in pancreatic cancer cell migration, invasion, and adhesion. BMC Cancer 15:266

    Article  PubMed Central  PubMed  Google Scholar 

  36. Rivera VT, Boudoukha S, Simon A et al (2014) Post-transcriptional regulation of cyclins D1, D3 and G1 and proliferation of human cancer cells depend on IMP-3 nuclear localization. Oncogene 33:2866–2875

    Article  Google Scholar 

  37. Su P, Hu J, Zhang H et al (2014) IMP3 expression is associated with epithelial-mesenchymal transition in breast cancer. Int J Clin Exp Pathol 7:3008–3017

    PubMed Central  CAS  PubMed  Google Scholar 

  38. Nemunaitis J, Meyers T, Senzer N et al (2006) Phase I trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer. Mol Therapy 13:1185–1191

    Article  CAS  Google Scholar 

Download references

Acknowledgments

We thank Professor Hong Shen for providing LAC cell lines. This study was supported by National Natural Science Foundation of China (Grant Number: 81470013) and Natural Science Foundation of Guangdong Province (Grant Number: 2015A030313244).

Author information

Author notes

    Authors and Affiliations

    1. Department of Pathology, School of Basic Medical Science, Southern Medical University, Guangzhou, China

      Jinhai Yan, Wenjing Jian, Bo Qiu, Jing Wen & Xinhua Zhou

    2. Department of Pathology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China

      Jinhai Yan

    3. Department of Pathology, The Third Affiliated Hospital of Southern Medical University, Zhongshan Dadaoxi, Street No. 183, Guangzhou, 510630, China

      Qingzhu Wei, Jianghuan Liu, Bo Fu & Tong Zhao

    Authors
    1. Jinhai Yan
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Qingzhu Wei
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Wenjing Jian
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Bo Qiu
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Jing Wen
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Jianghuan Liu
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Bo Fu
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Xinhua Zhou
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. Tong Zhao
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Tong Zhao.

    Ethics declarations

    Conflict of interest

    The authors declare no competing interests.

    Additional information

    Jinhai Yan and Qingzhu Wei have contributed equally to this work.

    Electronic supplementary material

    Below is the link to the electronic supplementary material.

    Supplementary material 1 (DOC 66 kb)

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Yan, J., Wei, Q., Jian, W. et al. IMP3 Predicts Invasion and Prognosis in Human Lung Adenocarcinoma. Lung 194, 137–146 (2016). https://doi.org/10.1007/s00408-015-9829-0

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s00408-015-9829-0

    Keywords

    Search

    Navigation